(1) Five candidate biomarkers (including FCGR2A, GSDMB, MIR330, MED1, and SQSTM1) were identified, which might most effectively differentiate the post-MI HF patients from those without HF. The gene discussed is FCGR2A; the disease is hydrops fetalis.